X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (50) 50
female (34) 34
index medicus (29) 29
male (29) 29
physics (27) 27
condensed matter (24) 24
middle aged (22) 22
adult (20) 20
aged (18) 18
condensed matter - materials science (18) 18
materials science (18) 18
cancer (17) 17
hematology (17) 17
oncology (16) 16
[ phys.cond.cm-ms ] physics [physics]/condensed matter [cond-mat]/materials science [cond-mat.mtrl-sci] (15) 15
physics - materials science (15) 15
aged, 80 and over (13) 13
animals (13) 13
antineoplastic combined chemotherapy protocols - therapeutic use (13) 13
life sciences (13) 13
[phys.cond.cm-ms]physics [physics]/condensed matter [cond-mat]/materials science [cond-mat.mtrl-sci] (12) 12
prognosis (12) 12
lymphoma (11) 11
lymphomas (11) 11
chemotherapy (10) 10
disease-free survival (10) 10
physics, applied (10) 10
rituximab (10) 10
atherosclerosis (9) 9
biochemistry & molecular biology (9) 9
peripheral vascular disease (9) 9
survival (9) 9
survival analysis (9) 9
treatment outcome (9) 9
analysis (8) 8
b-cell lymphoma (8) 8
non-hodgkins-lymphoma (8) 8
patients (8) 8
lymphoma, large b-cell, diffuse - drug therapy (7) 7
magnetization reversal (7) 7
materials science, multidisciplinary (7) 7
retrospective studies (7) 7
[ phys.cond.cm-gen ] physics [physics]/condensed matter [cond-mat]/other [cond-mat.other] (6) 6
[sdv.can]life sciences [q-bio]/cancer (6) 6
adolescent (6) 6
antineoplastic combined chemotherapy protocols - administration & dosage (6) 6
clinical trials (6) 6
cyclophosphamide (6) 6
cyclophosphamide - administration & dosage (6) 6
endothelial-cells (6) 6
follow-up studies (6) 6
gene-expression (6) 6
low-density-lipoprotein (6) 6
lymphocytes b (6) 6
lymphoma, large b-cell, diffuse - mortality (6) 6
magnetic fields (6) 6
other (6) 6
physics, condensed matter (6) 6
prospective studies (6) 6
therapy (6) 6
[ phys ] physics [physics] (5) 5
[ sdv.can ] life sciences [q-bio]/cancer (5) 5
antibodies, monoclonal, murine-derived - administration & dosage (5) 5
antineoplastic combined chemotherapy protocols - adverse effects (5) 5
cells (5) 5
cells, cultured (5) 5
disease (5) 5
disease progression (5) 5
domain walls (5) 5
doxorubicin - administration & dosage (5) 5
drug administration schedule (5) 5
france (5) 5
further section (5) 5
macrophages - metabolism (5) 5
magnetization (5) 5
mice (5) 5
micromagnetics (5) 5
nanowires (5) 5
prednisone - administration & dosage (5) 5
response criteria (5) 5
risk factors (5) 5
trial (5) 5
usage (5) 5
young adult (5) 5
abridged index medicus (4) 4
care and treatment (4) 4
condensed matter - mesoscale and nanoscale physics (4) 4
dose-response relationship, drug (4) 4
dynamics (4) 4
elderly-patients (4) 4
fatty-acids (4) 4
fdg-pet (4) 4
films (4) 4
gene expression (4) 4
hematology, oncology and palliative medicine (4) 4
hemic and lymphatic diseases (4) 4
in-vivo (4) 4
international workshop (4) 4
macrophages (4) 4
mice, transgenic (4) 4
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Infectious Diseases, The, ISSN 1473-3099, 2017, Volume 17, Issue 5, pp. 510 - 519
Summary Background Listeriosis is a severe foodborne infection and a notifiable disease in France. We did a nationwide prospective study to characterise its... 
Infectious Disease | MORTALITY | MENINGITIS | INFECTIOUS DISEASES | MONOCYTOGENES | RISK-FACTORS | MANAGEMENT | GUIDELINES | SURVEILLANCE | PREGNANCY | Foodborne Diseases - microbiology | Infant, Newborn, Diseases - epidemiology | Prognosis | Prospective Studies | Humans | Listeriosis - diagnosis | Bacteremia - mortality | Male | Infant, Newborn, Diseases - microbiology | Listeriosis - epidemiology | Mandatory Reporting | Listeria monocytogenes - classification | Adult | Female | Pregnancy Complications, Infectious - microbiology | Infant, Newborn | Meningoencephalitis - epidemiology | France - epidemiology | Meningoencephalitis - mortality | Pregnancy Complications, Infectious - epidemiology | Risk Factors | Listeria monocytogenes - isolation & purification | Hospitalization | Infectious Disease Transmission, Vertical | Pregnancy | Meningoencephalitis - microbiology | Bacteremia - epidemiology | Listeriosis - microbiology | Aged | Population Surveillance | Listeriosis | Neonates | Food-borne diseases | Disease | Brain stem | Clinical trials | Infections | Genomes | Gestation | Epidemiology | Risk factors | Windows (intervals) | Listeria | Meningitis | Public health | Food | Dexamethasone | Bacterial infections | Mortality | Fetuses | Regression analysis | Clustering | Patients | Bacteremia | Meningoencephalitis | Studies | Surveillance | Medical prognosis | Health risk assessment | Cancer | Life Sciences
Journal Article
Lancet, The, ISSN 0140-6736, 2011, Volume 378, Issue 9806, pp. 1858 - 1867
Summary Background The outcome of diffuse large B-cell lymphoma has been substantially improved by the addition of the anti-CD20 monoclonal antibody rituximab... 
Internal Medicine | MEDICINE, GENERAL & INTERNAL | MULTICENTER | RESPONSE CRITERIA | AGGRESSIVE LYMPHOMAS | POOR-PROGNOSIS | NON-HODGKINS-LYMPHOMA | REGIMEN | YOUNG-PATIENTS | ELDERLY-PATIENTS | DES-LYMPHOMES | TRANSPLANTATION | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prospective Studies | Follow-Up Studies | Humans | Middle Aged | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Cyclophosphamide - adverse effects | Dose-Response Relationship, Drug | Young Adult | Vindesine - adverse effects | Adult | Female | Prednisolone | Doxorubicin - administration & dosage | Severity of Illness Index | Prednisone - administration & dosage | Lymphoma, Large B-Cell, Diffuse - drug therapy | Prednisone - adverse effects | Drug Administration Schedule | Risk Assessment | Rituximab | Treatment Outcome | Bleomycin - administration & dosage | Bleomycin - adverse effects | Vincristine | Lymphoma, Large B-Cell, Diffuse - mortality | Disease-Free Survival | Lymphoma, Large B-Cell, Diffuse - diagnosis | Maximum Tolerated Dose | Adolescent | Survival Analysis | Vindesine - administration & dosage | Doxorubicin - adverse effects | Chemotherapy | Physiological aspects | Lymphomas | B cells | Drug therapy | Methods | Cancer | Dehydrogenases | Toxicity | Population studies | Doxorubicin | Hepatitis | Randomization | Bleomycin | Motivation | Drug dosages | Neutropenia | Cell survival | Hematology | Prednisone | Survival | Patients | Lymphoma | Cyclophosphamide | Lymphocytes B | Monoclonal antibodies | CD20 antigen | Tumors | B-cell lymphoma | Clinical trials | Public speaking | Grants | Clinical medicine | Side effects | lymphoma | survival | International standardization | chemotherapy
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2013, Volume 14, Issue 6, pp. 525 - 533
Journal Article
Lancet Haematology, The, ISSN 2352-3026, 2017, Volume 4, Issue 1, pp. e46 - e55
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2011, Volume 12, Issue 5, pp. 460 - 468
Summary Background Diffuse large B-cell lymphoma is a common cancer in elderly patients. Although treatment has been standardised in younger patients, no... 
Hematology, Oncology and Palliative Medicine | MAINTENANCE RITUXIMAB | COLONY-STIMULATING FACTOR | PROGNOSTIC-FACTORS | RESPONSE CRITERIA | ONCOLOGY | AGGRESSIVE LYMPHOMAS | MALIGNANT-LYMPHOMAS | NON-HODGKINS-LYMPHOMA | COMPREHENSIVE GERIATRIC ASSESSMENT | DETUDE-DES-LYMPHOMES | CHOP CHEMOTHERAPY | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prognosis | Prospective Studies | Humans | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Cyclophosphamide - adverse effects | Aged, 80 and over | Vincristine - administration & dosage | Female | France | Odds Ratio | Doxorubicin - administration & dosage | Prednisone - administration & dosage | Lymphoma, Large B-Cell, Diffuse - drug therapy | Prednisone - adverse effects | Drug Administration Schedule | Lymphoma, Large B-Cell, Diffuse - pathology | Risk Assessment | Risk Factors | Rituximab | Treatment Outcome | Lymphoma, Large B-Cell, Diffuse - mortality | Disease-Free Survival | Analysis of Variance | Belgium | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Survival Analysis | Vincristine - adverse effects | Doxorubicin - adverse effects | Antibodies, Monoclonal, Murine-Derived - therapeutic use | Anthracyclines | Cyclophosphamide | Chemotherapy | Corticosteroids | Oncology, Experimental | Aged patients | Product development | Prednisone | Lymphomas | Research | Cancer | Toxicity | Albumin | Clinical trials | Multivariate analysis | Doxorubicin | Survival | Vincristine | Side effects | Motivation | Age | rituximab | B-cell lymphoma | Geriatrics | Neutropenia
Journal Article